|
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.
|
18563180 |
2008 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
|
18665147 |
2008 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.
|
18528295 |
2008 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We developed a mouse expressing human instead of mouse CTLA-4, allowing us to evaluate the independent contributions of CTLA-4 blockade of each T cell compartment during cancer immunotherapy in an in vivo model of mouse melanoma.
|
19581407 |
2009 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No significant differences were found between the distributions of CTLA-4 polymorphisms in the melanoma population compared with healthy controls.
|
21044351 |
2010 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using in vitro assays with human DCs, we demonstrated that DCs transfected with mRNA encoding a humanized anti-CTLA-4 mAb and mRNA encoding a soluble human GITR-L fusion protein enhance the induction of anti-tumor CTLs in response to DCs transfected with mRNAs encoding either melanoma or breast cancer antigens.
|
22028176 |
2011 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
In 2011 immunomodulation with ipilimumab, a monoclonal antibody targeting the ligand CTLA-4, has been approved for patients with advanced melanoma in first- and second-line treatment by the Food and Drug Administration (FDA) and in second-line treatment by the European Medicines Agency (EMA).
|
21802280 |
2011 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Triple combination of a blocking CTLA4 antibody with GVAX and anti-FR4 further enhanced overall survival and reduced growth of well-established melanomas.
|
23811319 |
2013 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.
|
23641913 |
2013 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, LXRβ activation displayed melanoma-suppressive cooperativity with the frontline regimens dacarbazine, B-Raf inhibition, and the anti-CTLA-4 antibody and robustly inhibited melanomas that had acquired resistance to B-Raf inhibition or dacarbazine.
|
24581497 |
2014 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two distinct approaches have emerged to try to extend survival in patients with metastatic melanoma: immunomodulation with anti-CTLA4 monoclonal antibodies, and targeted therapy with BRAF inhibitors or MEK inhibitors for BRAF-mutated melanoma.
|
24054424 |
2014 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previous analyses found no significant differences between the distributions of CTLA-4 polymorphisms in the melanoma population vs. controls, no significant difference in relapse free and overall survivals among patients and no correlation between autoimmunity and specific alleles.
|
24475110 |
2014 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that a combinatorial approach using CTLA-4 blockade with nonlymphodepletional ACT may promote additive endogenous and exogenous T-cell activities that enable greater therapeutic efficacy in the treatment of melanoma.
|
25658614 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This therapeutic approach has revolutionized cancer immunotherapy, and extraordinary increases in overall survival were noted, first with anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) and subsequently with anti-PD-1 (programmed cell death receptor-1) in melanoma and other malignancies.
|
26091825 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the role of antibodies that target CTLA-4 and PD-1 has been established in solid tumor malignancies and Food and Drug Administration approved for melanoma and non-small cell lung cancer, there remains a desperate need to incorporate immune checkpoint inhibition in hematologic malignancies.
|
27664133 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite the spectacular achievements of targeted therapies (BRAF inhibitors) or immuno-therapies (anti-CTLA4 or anti-PD1), most patients with melanoma will need additional treatments.
|
27756874 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PTML was strongly associated with clinical outcome to ipilimumab (anti-CTLA-4, three cohorts) and adoptive T-cell therapy (1 cohort) clinical outcome in melanoma.
|
27776519 |
2016 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We find that melanomas expressing high levels of CTLA4 separate into two distinct groups with respect to CD8 T-cell infiltration, which might influence clinical responses to anti-CTLA4 agents.
|
27549193 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens.
|
26940869 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
|
27549123 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antibodies against CTLA-4 and PD-1 also enhance the survival of melanoma patients.
|
26813076 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival after anti-CTLA4 immunotherapy in two independent cohorts of patients with melanoma (n = 174).
|
27668655 |
2016 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CAR-T cell-based therapies targeting CD19 can now induce durable remissions as well as prolong disease-free survival of patients with CD19 positive treatment refractory B cell malignancies and ICI-based therapies with humanized monoclonal antibodies against the T cell inhibitory receptors CTLA-4 and PD-1 as well as against the PD-1 ligand, PD-L1, can now achieve durable remissions as well as prolongation of life of a sizeable fraction of patients with melanoma and Hodgkin's lymphoma and non-small cell cancers.
|
28497159 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Many new treatment options in the last years, in particular targeted therapies (i.e. inhibitors of c-KIT, NRAS/MEK or BRAF) and immunotherapies (anti CTLA-4 and anti PD-1/PD-L1 antibodies), have changed the history of cutaneous melanoma.
|
28325255 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BRAF-mutated melanoma benefit from both anti-BRAF and anti-MEK targeted therapies while triple-negative melanomas could benefit from novel anti-CTLA-4 and anti-PD-L1 immunotherapeutic approaches.
|
29187493 |
2017 |